Novartis AG won U.S. Food and Drug Administration approval for the multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.
PTC Therapeutics to Acquire Agilis Biotherapeutics
Acquisitions, Angelman Syndrome, Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, Biologics License Application (BLA), Biotech, Business, CNS, Gene Therapy, Monogenic Diseases, Neurodegenerative Diseases, Neurological Disorders, Product PipelinesPTC Therapeutics Inc. announced an agreement to acquire Agilis Biotherapeutics Inc., a biotechnology company advancing an innovative gene therapy platform for rare monogenic diseases that affect the central nervous system.
Merz North America announced today that the U.S. Food and Drug Administration accepted for filing a supplemental Biologics License Application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients.
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Biotechnology, Central Nervous System, CNS Disorders, Collaboration, Duchenne Muscular Dystrophy (DMD), Frontotemporal Dementia (FTD), Genes, Huntingtin (HTT) Gene, Huntington’s disease, Issue Archives, Parkinson’s disease, Spinocerebellar Ataxia Type 3 (SCA3)Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.